Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone
Why the study?
Does omapatrilat reduce blood pressure in subjects with hypertension nonresponsive to hydrochlorothiazide alone?
Population
274 subjects with mild to severe hypertension nonresponsive to hydrochlorothiazide alone
Comparison
Omapatrilat added to 25 mg of hydrochlorothiazide vs Matching placebo added to 25 mg of…
Design
RCT, randomized, double-blind, matching placebo
Follow-up
8 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports adding omapatrilat to HCTZ for uncontrolled hypertension; extends RCT evidence in resistant cases.
Structured PICO
Does omapatrilat reduce blood pressure in subjects with hypertension nonresponsive to hydrochlorothiazide alone?
P
Population
274 subjects with mild to severe hypertension nonresponsive to hydrochlorothiazide alone
I
Intervention
Omapatrilat (10 or 20 mg, electively titrated to 20 or 40 mg at week 4 if seated diastolic blood pressure was >= 90 mm Hg) added to 25 mg of hydrochlorothiazide
C
Comparator
Matching placebo added to 25 mg of hydrochlorothiazide
O
Outcome
Change in seated diastolic blood pressure (SeDBP) from baseline to week 8surrogate
Omapatrilat provides significant additional blood pressure reduction and is well tolerated when added to hydrochlorothiazide in patients with hypertension not controlled by hydrochlorothiazide alone.
Cite This Study
Ferdinand et al. (2001) studied this question.